News
MedWatch Article
16 Jan 2024
Droplet IV has been granted the special Safer Technologies Program (STeP) designation by the FDA, which will significantly reduce the time it takes to obtain regulatory approval.
This allows Droplet IV to adhere their project timeline and eventually enter the US market in 2025.
TV2 Bornholm News
3 November 2023
Tore was interviewed at Bornholm’s Hospital, where the discovery took place. Droplet IV was developed as part of the BioMedical Design Novo Nordisk Foundation Fellowship Programme during a four-month stay at the hospital in 2021.
Tore illustrates how the current time-consuming task of manually flushing IV lines can be replaced by Droplet IV.
This saves nurses time when administering medicine to patients, allowing them to focus on other important tasks.
Entering BioInnovation Institute
23 April 2023
Only a few months after receiving the honorable award from Danish Tech Challenge, Droplet IV entered the BioInnovation Institute’s Venture Lab program. It offers help to early-stage start-ups within human health and planetary health.
The teams reaction:
“Joining the BII community provides access to expertise and mentorship, shared infrastructure and resources, investment and funding opportunities, and regulatory and legal knowledge. Perhaps most importantly, it makes us part of a collaborative community that is enormously inspiring and helpful for our journey.”
Winning Danish Tech Challenge
20 January 2023
Droplet IV won the Danish Tech Challenge. Seen here awarded the winning prize by His Royal Highness the Crown Prince.
Life Science Award 2022
Marts 2023
Droplet IV received in 2022 a Life Science Micro grant from Bristol Myers Squibb and the Foundation for Entrepreneurship.
“We are sincerely grateful for this generous support, as it empowers us to continue our development journey and brings us closer to introducing Droplet IV to the market.”
- Droplet IV